Pfizer (PFE) EBT Margin (2009 - 2026)
Pfizer (PFE) reported EBT Margin of 135.53% for Q1 2026, up 372.0% year-over-year from 28.71% in Q1 2025, and up 1549.13% quarter-over-quarter from 9.35% in Q4 2025.
Pfizer (PFE) EBT Margin (2009 - 2026) Analysis & Trends
Pfizer (PFE) has 18 years of EBT Margin data on file, last reported at 135.53% in Q1 2026.
- EBT Margin for Q1 2026 came in at 135.53%, up 372.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 32.31% (down 291.0% YoY), and the FY2025 annual result was 12.02%, down 8363.0% from the prior year.
- EBT Margin climbed to 135.53% in Q1 2026 per PFE's latest filing, from 9.35% in the prior quarter.
- Over five years, EBT Margin peaked at 1066.74% in Q3 2024 and troughed at 203.77% in Q4 2023.
- A 5-year average of 110.41% and a median of 41.26% in 2022 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2024 and 2025: EBT Margin soared 127051 bps in 2024, then plunged 92166 bps in 2025.
- A 5-year view of EBT Margin shows it stood at 39.76% in 2022, then sank by 402 bps to 120.24% in 2023, then surged by 987 bps to 1066.74% in 2024, then sank by 101 bps to 9.35% in 2025, then surged by 1549 bps to 135.53% in 2026.
- Business Quant data shows PFE's EBT Margin at 135.53% in Q1 2026, 9.35% in Q4 2025, and 145.08% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 28.10% |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 44.70% |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 24.89% |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 6.93% |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -21.49% |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 24.18% |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 37.07% |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 135.53% |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 28.20% |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 135.53% |
| Dec 31, 2025 | -9.35% |
| Sep 28, 2025 | 145.08% |
| Jun 29, 2025 | 133.92% |
| Mar 30, 2025 | 131.80% |
| Sep 29, 2024 | 1,066.74% |
| Jun 30, 2024 | -0.78% |
| Mar 31, 2024 | 22.99% |
| Dec 31, 2023 | -120.24% |
| Oct 1, 2023 | -203.77% |
| Jul 2, 2023 | 65.01% |
| Apr 2, 2023 | 172.87% |
| Oct 2, 2022 | 39.76% |
| Jul 3, 2022 | 41.26% |
| Apr 3, 2022 | 35.27% |
| Oct 3, 2021 | 32.63% |
| Jul 4, 2021 | 36.77% |
| Apr 4, 2021 | 39.21% |
| Sep 27, 2020 | 5.55% |
| Jun 28, 2020 | 30.68% |